Tag: AACR

Preliminary results from the ongoing Phase 1 study (NCT06555744) evaluating ZW191, an antibody-drug conjugate (see ADC Drugmap) targeting folate receptor-alpha (FR⍺), were presented at...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-902, a Trophoblast cell surface antigen 2 (TROP2-) targeting ADC (see ADC Drugmap) being developed by OBI Pharma.

During AACR 2025 representatives of multiple Chinese biotech companies demonstrating the diversity and cutting-edge advancements innovations in the development of novel antibody-drug conjugates (ADC),

Research (AACR) Annual Meeting in Chicago, Illinois, held from April 25 to 30, 2025 will include positive preclinical data highlighting the potential of micvotabart pelidotin (formerly referred to as PYX-201; see ADC Drugmap), a first-in-concept antibody-drug conjugate (ADC) being developed by Pyxis Oncology. The drug is composed of a fully human IgG1 antibody, a cleavable mcValCitPABC linker, and four Auristatin 0101 (Aur0101, PF-06380101) payload molecules.

During the upcoming annual meeting of the American Association for Cancer research, in Chicago, Illinois, held from April 25 to 30, 2025, Heidelberg Pharma will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform.

Preclinical data for ADRX-0706, a fully proprietary investigational antibody=drug conjugate or ADC being developed by Adcentrx, will be presented at the American Association for Cancer...

José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...

Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a broad range of FRα expression...

Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going Phase I dose-escalation phase clinical...

The novel coronavirus, also known as COVID19, is prompting major medical societies and healthcare organizations to cancel conferences and events around the world. The decision...